open–labeled, multicenter phase II study of the evaluation of single administration Pegfilgrastim once per cycle as an adjunct to R-FC (rituximab plus fludarabine and cyclophosphamide) or FC combination chemotherapy in patients with newly diagnosed or relapsed chronic lymphocytic leukemia

Trial Profile

open–labeled, multicenter phase II study of the evaluation of single administration Pegfilgrastim once per cycle as an adjunct to R-FC (rituximab plus fludarabine and cyclophosphamide) or FC combination chemotherapy in patients with newly diagnosed or relapsed chronic lymphocytic leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top